A fourth of patients with advanced, anti-PD-1-resistant melanoma responded to the viral mimetic BO-112 plus pembrolizumab. Responses were durable with over half of responding patients alive at 24 ...
MedPage Today on MSN
PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma
First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but ...
Combining PD-L1 blockade with pharmacological HPK1 inhibition overcomes tumors with low antigenicity
An article by Daiichi Sankyo Co. Ltd. scientists reports data from a study designed to assess the potential of combining pharmacological inhibition of hematopoietic progenitor kinase 1 (HPK1) with ...
A phase 2 trial shows that PD-1 blockade can safely replace surgery for many early-stage dMMR cancers, offering patients a chance at a cure without invasive operations. Study: Nonoperative Management ...
Shanghai Henlius Biotech, Inc. Class H ( ($HK:2696) ) has shared an update. Shanghai Henlius Biotech has initiated a first-in-human phase 1 ...
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback